Nanoemulsion-Based Intranasal Vaccine Platform Has Potential to Address
a Range of Diseases
in Developing Countries, Including Influenza,
Hepatitis B and Respiratory Syncytial Virus
ANN ARBOR, Mich., (October 25, 2010) – NanoBio Corporation today announced that company founder and chief executive officer James R. Baker, Jr. MD, will participate in the 6th Annual Grand Challenges in Global Health (GCGH) Meeting, taking place from Oct. 25-27 in Seattle, Wash., to present data illustrating the potential of the company’s nanoemulsion-based needle-free intranasal vaccine platform.
GCGH supports research projects that aim to achieve scientific breakthroughs needed to prevent, treat, and cure diseases of the developing world, which lacks the infrastructure to provide adequate healthcare to a population that is at risk for highly transmissible diseases. One goal of the GCCH is to improve the delivery and stability of vaccines to make them easier to transport and quicker to administer.
At the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), NanoBio presented Phase 1 clinical data demonstrating that the company’s nanoemulsion-adjuvanted intranasal flu vaccine, NB-1008, is safe, well tolerated and elicits both mucosal and systemic immune responses following a single intranasal vaccination in a study of 199 healthy adults. This successful first-in-man study of NanoBio’s intranasal vaccine program provides a clear pathway for further development in influenza, as well as other diseases with unmet medical needs. Dr. Baker will highlight the Phase 1 data during his presentation at the GCGH conference and will speak to the potential of nanoemulsion-based needle-free vaccines to address pandemic health concerns in developing countries.
“The unique ability of NB-1008 to elicit both mucosal and systemic immunity represents a major breakthrough for vaccines, particularly for respiratory and sexually transmitted diseases. In addition, the needle-free administration and thermal stability of nanoemulsion vaccines can positively impact populations where trained personnel are not available to provide injectable vaccines in a sterile environment,” said Dr. Baker.
Dr. Baker presentation will take place on Monday, October 25th, 10-1030 a.m.
About Grand Challenges in Global Health
The Grand Challenges in Global Health (GCGH) initiative is a major research effort to achieve scientific breakthroughs against diseases that kill millions of people each year in the world’s poorest countries. The goal of the initiative is to create “deliverable technologies” – health tools that are not only effective, but also inexpensive to produce, easy to distribute, and simple to use in developing countries.
NanoBio Corporation is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are treatments for herpes labialis (licensed to GSK in the U.S. and Canada), onychomycosis, acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.